<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>H. Fassnacht-Riederle | Pfau Lab</title>
    <link>https://pfaulab.org/author/h.-fassnacht-riederle/</link>
      <atom:link href="https://pfaulab.org/author/h.-fassnacht-riederle/index.xml" rel="self" type="application/rss+xml" />
    <description>H. Fassnacht-Riederle</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><copyright>Â© {2022} Maximilian Pfau</copyright><lastBuildDate>Thu, 01 Jan 2015 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://pfaulab.org/media/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_512x512_fill_lanczos_center_3.png</url>
      <title>H. Fassnacht-Riederle</title>
      <link>https://pfaulab.org/author/h.-fassnacht-riederle/</link>
    </image>
    
    <item>
      <title>Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion</title>
      <link>https://pfaulab.org/publication/pmid-26413794/</link>
      <pubDate>Thu, 01 Jan 2015 00:00:00 +0000</pubDate>
      <guid>https://pfaulab.org/publication/pmid-26413794/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
